Phase 1 safety and efficacy of IMC-F106C, a PRAME × CD3 ImmTAC bispecific, in post-checkpoint cutaneous melanoma (CM). This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I. This ...
Thank you for submitting your question. Keep reading Forbes Advisor for the chance to see the answer to your question in one of our upcoming stories. Our editors also may be in touch with follow-up ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results